Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease;Incremento de las HDL como arma terapéutica en la aterotrombosis

Revista Espanola de Cardiologia

Volumn 63, Issue 3, 2010, Pages 323-333

  Badimón, Juan José ^a   Ibáñez, Borja ^b,c  

^a Aterotrombosis Instituto Cardiovascular Hospital Mount Sinai Nueva York Estados Unidos   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Atherosclerosis; HDL; Inflammation; Lipoproteins; Vulnerable plaque

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; THROMBOSIS;

ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS, HDL; THROMBOSIS;

EID: 77950569030     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(10)70091-9     Document Type: Review

References (83)

1. Ignatowski AC. Influence of animal food on the organism of rabbits. Reports of the Imperial Military Academy (St. Petersburg). 1908;16:154-73.
2. Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arterioscler Thromb Vasc Biol. 1983;3;178-182.
3. Ibáñez B., Vilahur G., and Badimón J. Plaque progression and regression in atherothrombosis. J Thromb Haemost 5 (2007) 292-299
4. Williams K.J., and Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9 (1998) 471-474
5. Rong J.X., Rangaswamy S., Shen L., Dave R., Chang Y.H., Peterson H., et al. Arterial injury by cholesterol oxidation products causes endothelial dysfunction and arterial wall cholesterol accumulation. Arterioscler Thromb Vasc Biol 18 (1998) 1885-1894
6. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004) III27-III32
7. Behrendt D., and Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 90 (2002) L40-L48
8. Hutter R., Valdiviezo C., Sauter B.V., Savontaus M., Chereshnev I., Carrick F.E., et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 109 (2004) 2001-2008
9. Skalen K., Gustafsson M., Rydberg E.K., Hulten L.M., Wiklund O., Innerarity T.L., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417 (2002) 750-754
10. Geng Y.J., Phillips J.E., Mason R.P., and Casscells S.W. Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture. Biochem Parmacol 66 (2003) 1485-1492
11. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., and Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 (1987) 1371-1375
12. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
13. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
14. Sambola A., Osende J., Hathcock J., Degen M., Nemerson Y., Fuster V., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 (2003) 973-977
15. Mallat Z., and Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 88 (2001) 998-1003
16. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108 (2003) 1664-1672
17. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
18. Ray K.K., and Cannon C.P. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 15 (2004) 637-643
19. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 354 (1999) 708-715
20. Brewer Jr. H.B. Increasing HDL cholesterol levels. N Engl J Med 350 (2004) 1491-1494
21. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
22. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117 (2007) 746-756
23. Williamson R., Lee D., Hagaman J., and Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A 89 (1992) 7134-7138
24. Moore R.E., Navab M., Millar J.S., Zimetti F., Hama S., Rothblat G.H., et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 97 (2005) 763-771
25. Tangirala R.K., Tsukamoto K., Chun S.H., Usher D., Pure E., and Rader D.J. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100 (1999) 1816-1822
26. Cimmino G, Chen W, Speidl WS, Giannarelli C, Ibanez B, Fuster V, et al. Safe and sustained over-expression of functional ApoA-I/HDL in ApoA-I null mice by muscular AAV8 gene transfer. J Cardiovasc Pharmacol. 2009 Aug 20 [Epub ahead of print].
27. Brinton E.A., Eisenberg S., and Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14 (1994) 707-720
28. Hamilton R.L., Williams M.C., Fielding C.J., and Havel R.J. Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver. J Clin Invest 58 (1976) 667-680
29. Green P.H., Tall A.R., and Glickman R.M. Rat intestine secretes discoid high density lipoprotein. J Clin Invest 61 (1978) 528-534
30. Timmins J.M., Lee J.Y., Boudyguina E., Kluckman K.D., Brunham L.R., Mulya A., et al. Targeted inactivation of hepatic ABCA1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115 (2005) 1333-1342
31. Brunham L.R., Kruit J.K., Iqbal J., Fievet C., Timmins J.M., Pape T.D., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 116 (2006) 1052-1062
32. Cuchel M., and Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 113 (2006) 2548-2555
33. Yancey P.G., Bortnick A.E., Kellner-Weibel G., De la Llera-Moya M., Phillips M.C., and Rothblat G.H. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23 (2003) 712-719
34. Kennedy M.A., Barrera G.C., Nakamura K., Baldan A., Tarr P., Fishbein M.C., et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 1 (2005) 121-131
35. Curtiss L.K., Valenta D.T., Hime N.J., and Rye K.A. What is so special about apolipoprotein AI in reverse cholesterol transport?. Arterioscler Thromb Vasc Biol 26 (2006) 12-19
36. Glomset J.A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9 (1968) 155-167
37. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 1529 (2000) 245-256
38. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
39. Shah P.K. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J 28 (2007) 5-12
40. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
41. Glass C., Pittman R.C., Weinstein D.B., and Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Natl Acad Sci U S A 80 (1983) 5435-5439
42. Trigatti B.L., Krieger M., and Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 1732-1738
43. Schwartz C.C., Halloran L.G., Vlahcevic Z.R., Gregory D.H., and Swell L. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science 200 (1978) 62-64
44. Mineo C., Deguchi H., Griffin J.H., and Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 98 (2006) 1352-1364
45. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
46. Choi B.G., Vilahur G., Yadegar D., Viles-Gonzalez J.F., and Badimon J.J. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 6 (2006) 571-587
47. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
48. Kannel W.B. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 52 (1983) B9-B12
49. Genest J.J., McNamara J.R., Salem D.N., and Schaefer E.J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67 (1991) 1185-1189
50. Miller G.J., and Miller N.E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1 (1975) 16-19
51. Badimón J.J., Badimón L., Gálvez A., Dische R., and Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 60 (1989) 455-461
52. Badimón J.J., Badimón L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
53. Badimon J.J., Fuster V., and Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation 86 (1992) III86-III94
54. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
55. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
56. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
57. Lee J.M., Robson M.D., Yu L.M., Shirodaria C.C., Cunnington C., Kylintireas I., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 54 (2009) 1787-1794
58. Paolini J.F., Mitchel Y.B., Reyes R., Kher U., Lai E., Watson D.J., et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 101 (2008) 625-630
59. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
60. De Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., De Graaf J., Zwinderman A.H., Posma J.L., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
61. Clark R.W., Sutfin T.A., Ruggeri R.B., Willauer A.T., Sugarman E.D., Magnus-Aryitey G., et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
62. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
63. Vergeer M., Bots M.L., Van Leuven S.I., Basart D.C., Sijbrands E.J., Evans G.W., et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118 (2008) 2515-2522
64. Stein E.A., Stroes E.S., Steiner G., Buckley B.M., Capponi A.M., Burgess T., et al. Safety and tolerability of dalcetrapib. Am J Cardiol 104 (2009) 82-91
65. Cannon C.P., Dansky H.M., Davidson M., Gotto Jr. A.M., Brinton E.A., Gould A.L., et al. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J 158 (2009) 513-519
66. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
67. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
68. Franceschini G., Sirtori C.R., Capurso A., Weisgraber K.H., and Mahley R.W. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 66 (1980) 892-900
69. Weisgraber K.H., Bersot T.P., Mahley R.W., Franceschini G., and Sirtori C.R. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest 66 (1980) 901-907
70. Sirtori C.R., Calabresi L., Franceschini G., Baldassarre D., Amato M., Johansson J., et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 103 (2001) 1949-1954
71. Ameli S., Hultgardh-Nilsson A., Cercek B., Shah P.K., Forrester J.S., Ageland H., et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 90 (1994) 1935-1941
72. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97 (1998) 780-785
73. Kaul S., Coin B., Hedayiti A., Yano J., Cercek B., Chyu K.Y., et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol 44 (2004) 1311-1319
74. Marchesi M., Booth E.A., Davis T., Bisgaier C.L., and Lucchesi B.R. Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther 311 (2004) 1023-1031
75. Wang L., Sharifi B.G., Pan T., Song L., Yukht A., and Shah P.K. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol 48 (2006) 1459-1468
76. Parolini C., Chiesa G., Gong E., Caligari S., Cortese M.M., Koga T., et al. Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis 183 (2005) 222-229
77. Chiesa G., Monteggia E., Marchesi M., Lorenzon P., Laucello M., Lorusso V., et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 90 (2002) 974-980
78. Ibáñez B., Vilahur G., Cimmino G., Speidl W.S., Pinero A., Choi B.G., et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 51 (2008) 1104-1109
79. Parolini C., Marchesi M., Lorenzon P., Castano M., Balconi E., Miragoli L., et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-IMilano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 11 (2008) 1098-1103
80. Ibáñez B., Cimmino G., Benezet-Mazuecos J., Santos-Gallego C.G., Pinero A., Prat-Gonzalez S., et al. Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis 202 (2009) 185-191
81. Ibáñez B., Pinero A., Orejas M., and Badimón J.J. Nuevas técnicas de imagen para la cuantificación de la carga aterosclerótica global. Rev Esp Cardiol 60 (2007) 299-309
82. Cimmino G., Ibáñez B., Vilahur G., Speidl W.S., Fuster V., and Badimón L. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by apoA-I. J Cell Mol Med (2008) Dec 16 [Epub ahead of print]
83. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933